Evaluation of Repotrectinib's Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone in Vitro and Ex Vivo von Chen, Haiming, Souther, Eric, Li, Mingjie, Goldwater, Marissa-Skye, Behare, Stacy, Hekmati, Ava, Yu, Huixin, Nassir, Isabella, Nassir, Ariella, Xu, Ning, Berenson, James R.

Volltext

The JAK Inhibitor Pacritinib Suppresses the Checkpoint Proteins Pvrig and Tigit Expression on T Cells in Multiple Myeloma Patients von Xu, Ning, Li, Mingjie, Goldwater, Marissa-Skye, Behare, Stacy, Hekmati, Ava, Yu, Huixin, Nassir, Isabella, Nassir, Ariella, Deighton, Charles David, Chen, Haiming, Berenson, James R.

Volltext

Ruxolitinib Enhances Anti-MM Function of Cytotoxic T-Cells By Upregulating IFNγ and Gzmb von Chen, Haiming, Li, Mingjie, Goldwater, Marissa-Skye, Behare, Stacy, Hekmati, Ava, Yu, Huixin, Nassir, Isabella, Nassir, Ariella, Deighton, Charles David, Xu, Ning, Berenson, James R.

Volltext

Repotrectinib Alone and in Combination with Immunomodulatory Drugs Exhibits Potent Anti-Multiple Myeloma Activity von Chen, Haiming, Souther, Eric, Li, Mingjie, Goldwater, Marissa-Skye, Behare, Stacy, Hekmati, Ava, Yu, Huixin, Nassir, Isabella, Nassir, Ariella, Xu, Ning, Berenson, James R.

Volltext